BLACK WEEKSFlaconcini −15% · kit −10% · resto −5%con il codiceSpedizione gratuita in Germania da 200 €

Questa pagina è stata tradotta automaticamente e può contenere errori. Sei madrelingua? Saremo felici di ricevere il tuo feedback e le tue correzioni.Invia feedback

The Peptide Desk The Peptide Desk
KPV Oral, foto del prodotto
Immune Oral

KPV Oral

Immune Oral

  • Spedito dalla Germania

Ordine

Prezzo unitario - Spedizione gratuita in Germania da 200 € durante le Black Weeks
  • DHL con tracciamento
  • Imballaggio discreto

4.6 su 5 su Trustpilot73 recensioni

In sintesi

KPV Oral in cifre

I dati chiave dalla nostra enciclopedia.

Voce completa dell'enciclopedia
Class
Anti-inflammatory tripeptideoral
Use
Oraltablet, 500mcg
Sizes
250 to 500 mcg2 sizes in the shop

Non esiste ancora un'analisi di laboratorio per KPV Oral. Vota a favoreFallo testare tu, noi paghiamo la metàTutte le analisi di laboratorio

Conoscenze

Tutto su KPV Oral

Informazioni dettagliate in arrivo.

Dosaggio

Caricamento informazioni sul dosaggio …

Di più nell'enciclopedia

FAQ

Domande frequenti

Fonti per ogni risposta: voce dell'enciclopedia

Hai ancora una domanda?

Scrivici, il nostro team ti aiuterà.

Are there studies on KPV as a tablet?

No. There is no published study on the tablet. The gut studies in mice also gave KPV by mouth, though: in drinking water or in carriers that release the compound only in the colon.

Is KPV approved or studied in humans?

No. There is no approval and as of 26 October 2026 ClinicalTrials.gov lists not a single trial with KPV. All data come from cell experiments and animal models.

Why via the gut in particular?

The transporter PepT1 carries small peptides of two or three building blocks into cells, KPV included. PepT1 is barely present in the healthy colon but increased in chronic bowel inflammation. So KPV preferentially reaches the inflamed areas. In mice without PepT1 the effect of KPV on colon tumours after inflammation was absent.

What do the gut models show?

With KPV in the drinking water the inflammation marker MPO fell by about 50 and 30 percent of the rise (two colitis models) and weight loss was smaller. In a model of colon cancer after inflammation fewer tumours formed, but not in a genetic tumour model without inflammation.

What do carriers like nanoparticles add?

They protect KPV on its way through stomach and small intestine and release it in the colon. In nanoparticles a 12,000-fold lower concentration gave a similar effect. A newer conjugate brought 3.8 times more KPV into the colon and worked better even at a 20-fold smaller amount.

Which side effects are known?

There are no solid data because KPV has never been tested in a registered human trial. The nanoparticle carriers did not damage gut cells in cell experiments. That cannot be transferred to humans.